Risperdal vs. Invega

See how Risperdal and Invega compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Risperdal and Invega are both atypical antipsychotics, and Invega's active ingredient is actually the metabolite Risperdal breaks down into in the body.

  • Risperdal needs a titration step before reaching its maintenance dose, while Invega's extended-release tablet is taken at a fixed dose from day one.

  • Risperdal covers bipolar disorder and pediatric autism-related irritability, while Invega's FDA approval is limited to schizophrenia and schizoaffective disorder.

Risperdal vs. Invega Drug Summary

Risperdal

Risperdal (risperidone) is an atypical antipsychotic approved for schizophrenia, acute manic or mixed episodes of bipolar I disorder, and irritability linked to autistic disorder in children. It comes as a tablet, oral solution, or orally disintegrating tablet, and treatment usually starts at 2 mg once daily before moving to a maintenance dose of 4 mg to 8 mg.

Invega

Invega (paliperidone) is an atypical antipsychotic approved for schizophrenia and schizoaffective disorder in adults. It is taken as a once-daily extended-release tablet at a fixed dose between 3 mg and 12 mg, with no titration period needed.

Risperdal vs. Invega Side Effects

Risperdal

Most common
insomnia (up to 32%)
somnolence (up to 25%)
parkinsonism (up to 17%)
dizziness (up to 14%)

Invega

Most common
insomnia (up to 15%)
extrapyramidal symptoms (up to 13%)
akathisia (up to 12%)
headache (up to 10%)

Risperdal vs. Invega Dosage

Risperdal

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 2 mg once daily Day 1
Maximum dose 2 mg once daily Same as starting
Dose changes None Fixed dose

Invega

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 6 mg once daily At the start
Maximum dose 12 mg once daily If needed
Dose changes 3 increases As tolerated

Risperdal vs. Invega Indications

Risperdal

Risperdal is FDA-approved for schizophrenia, acute manic or mixed episodes of bipolar I disorder, and irritability associated with autistic disorder in children and adolescents. It is also used off-label for OCD augmentation and for tic disorders like Tourette syndrome.

  • Schizophrenia in adults and adolescents (13-17 years)

  • Acute manic or mixed episodes of Bipolar I Disorder

  • Irritability associated with autistic disorder in children

  • Off-label: OCD augmentation and tic disorders/Tourette syndrome

Invega

Invega is FDA-approved for schizophrenia in adults and adolescents, and for schizoaffective disorder in adults, either alone or alongside mood stabilizers or antidepressants. It is not approved for bipolar disorder or pediatric irritability, unlike Risperdal.

  • Schizophrenia in adults and adolescents (12-17 years)

  • Schizoaffective disorder as monotherapy

  • Schizoaffective disorder adjunct to mood stabilizers/antidepressants

  • Not approved for bipolar disorder or dementia-related psychosis

Risperdal vs. Invega Pros and Cons

Risperdal

Risperdal has a broader set of FDA-approved uses, covering bipolar disorder and pediatric autism-related irritability in addition to schizophrenia. It has been on the market since 1993, giving prescribers decades of real-world experience with its dosing and side effect profile.

Pros

  • FDA-approved for bipolar disorder and autism-related irritability, not just schizophrenia

  • Available as tablet, oral solution, and orally disintegrating tablet for flexible dosing

  • Decades of clinical use since 1993 with well-established side effect data

  • Roughly $185 to $625 per month without insurance, generally lower than Invega

Cons

  • Requires a titration step before reaching the maintenance dose

  • Higher reported rates of insomnia and somnolence based on its own label

  • Pediatric schizophrenia approval starts at age 13, a year later than Invega

  • Only available in oral forms, with no long-acting injectable under this brand

Invega

Invega's extended-release tablet delivers a steady dose without a titration period, and its long-acting injectable versions offer monthly, every-3-month, or every-6-month dosing for patients who struggle with daily pills. Its FDA approval is narrower, limited to schizophrenia and schizoaffective disorder.

Pros

  • Fixed-dose extended-release tablet with no titration period required

  • Long-acting injectable options offer monthly, 3-month, or 6-month dosing

  • Renal dose adjustments allow tailored dosing for kidney impairment

  • Approved specifically for schizoaffective disorder, an indication Risperdal lacks

Cons

  • Narrower FDA approval, without bipolar or autism-related indications

  • Carries a specific QT-prolongation warning requiring caution with other drugs

  • Roughly $400 to $4,200 per month without insurance, higher than Risperdal

  • Newer drug with a shorter track record, approved in 2006 versus 1993

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.